Your browser doesn't support javascript.
loading
Feasibility and attractiveness of indication value-based pricing in key EU countries.
Flume, Mathias; Bardou, Marc; Capri, Stefano; Sola-Morales, Oriol; Cunningham, David; Levin, Lars-Ake; Touchot, Nicolas.
Afiliação
  • Flume M; Kassenärztliche Vereinigung Westfalen-Lippe, Dortmund, Germany.
  • Bardou M; CIC INSERM 1432, CHU du Bocage, Dijon, France.
  • Capri S; School of Economics and Management, Cattaneo-LIUC University, Castellanza, Italy.
  • Sola-Morales O; Health Innovation Technology Transfer, Barcelona, Spain.
  • Cunningham D; NHS South East Commissioning Support Unit, London, UK.
  • Levin LA; Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
  • Touchot N; groupH, London, UK.
Article em En | MEDLINE | ID: mdl-27226845
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use. We assessed how the reimbursement and pricing environment allows for IBP in seven European countries, evaluating both incentives and hurdles. In price setting countries such as France and Germany, the Health Technology Assessment and pricing process already accounts for differences of value across indications. In countries where differential value drives coverage decisions such as the United Kingdom and Sweden, IBP is likely to be used, at least partially, but not in the short-term. Italy is already achieving some form of differential value through managed entry agreements, whereas in Spain the electronic prescription system provides the infrastructure necessary for IBP but other hurdles exist.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Health_technology_assessment Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Health_technology_assessment Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos